Related Experiment Video
Updated: Jun 23, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Treatment of HIV infection with raltegravir
Lisa M Chirch1, Sidonie Morrison, Roy T Steigbigel
1Division of Infectious Diseases, Stony Brook University School of Medicine, Health Sciences Center T15-080, Stony Brook, NY 11794-8153, USA. lisa.chirch@stonybrook.edu
Background:
Raltegravir, an inhibitor of the HIV-1 integrase enzyme, is now available for the treatment of drug-resistant virus.
Objective:
To establish raltegravir as an effective addition to the existing antiretroviral armamentarium by reviewing pharmacokinetics, efficacy, safety and tolerability.
Methods:
Data from pharmacokinetic, Phase II and III clinical trials were reviewed.
Results/Conclusions:
Results from clinical trials indicate that raltegravir is safe and highly effective in the treatment of both antiretroviral-naïve and -experienced patients.
Related Concept Videos
Retrovirus Life Cycles
Antiviral Nucleoside Inhibitors
Inhibitors of Virion Maturation and Assembly
Retroviruses
Respiratory Syncytial Virus Disease
Size and Structure of Viral Genomes

